Price
No data yet.
Social Signal Score
70
5d
70
1 mentions
—
30d
70
1 mentions
—
60d
70
1 mentions
—
90d
70
1 mentions
—
news: 1
Company Profile
- Sector
- Financial Services
- Industry
- Asset Management
- Beta
- 0.56
- Country
- US
Quote
Day Range
$237.68 – $241.13
52-Week Range
$160.91 – $244.04
Volume
$3.1K
Market Cap
$458.94M
50-Day Avg
$207.21
200-Day Avg
$194.40
Prev Close
$241.23
Open
$241.13
Valuation & Ratios
P/E Ratio
—
EPS
—
P/B Ratio
—
P/S Ratio
—
Debt/Equity
—
Current Ratio
—
Dividend Yield
—
Gross Margin
—
Returns & Efficiency
Return on Equity
—
Return on Assets
—
FCF Yield
—
EV/EBITDA
—
Valuation
BBHhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
120Aug 24Aug 24
Social Signal Score
70
5d
70
1 mentions
—
30d
70
1 mentions
—
60d
70
1 mentions
—
90d
70
1 mentions
—
news: 1
Mentions (1)
- Newsseekingalpha.com·5h ago·Positive
BBH: Biotech's Next Growth Cycle Is Just Getting Started VanEck Biotech ETF (BBH) is a Buy, offering concentrated exposure to leading biotech firms entering a new growth cycle. BBH's top holdings—Amgen, Gilead, and Vertex—drive capital appreciation through diversified pipelines, strong cash flows, and expansion into new therapeutic areas. Despite a higher expense ratio and low yield, BBH's risk-reward profile is attractive given enduring demand and robust product pipelines.
View source ↗